Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Vitamin D insufficiency associated with higher risk of relapse attacks in patients with MS

Low vitamin D blood levels are associated with a significantly higher risk of relapse attacks in patients with multiple sclerosis (MS) who develop the disease during childhood, according to a study conducted by researchers from the University of California, San Francisco.

22 Jan 2010

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

AlphaRx Inc. announced today that its licensee, Gaia BioPharma Limited, has signed an agreement with a contract manufacturing organization (CMO), to manufacture GAI-122 for use in the planned Phase I and II clinical trials of that product candidate. GAI-122 is being developed as I.V. administered formulation of an intracellular neuroprotectant that employs AlphaRx's proprietary nano-emulsion formulation technology.

22 Jan 2010

Results of two pivotal Phase III clinical trials with oral FTY720 published

Results of the TRANSFORMS and FREEDOMS studies, the two pivotal Phase III clinical trials with oral FTY720 (fingolimod), have been published in The New England Journal of Medicine, providing comprehensive evidence to support the efficacy and safety profile of this first-in-class therapy for multiple sclerosis (MS).

21 Jan 2010

COTI's novel small molecule effective against pancreatic cancer in animal model

Critical Outcome Technologies Inc. announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility. This new series of experiments adds to the impressive data package for COTI-2, demonstrating efficacy both as a single agent and in combination with current first line therapies, as well as low toxicity in several different animal models of human cancers.

21 Jan 2010

EMD Serono announces results from CLARITY Phase III trial in MS patients

EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine. The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with relapsing-remitting multiple sclerosis (MS).

21 Jan 2010

New method for diagnosing post-traumatic stress disorder

Researchers at the University of Minnesota and Minneapolis VA Medical Center have identified a biological marker in the brains of those exhibiting post-traumatic stress disorder (PTSD).

20 Jan 2010

IMSMP signs a lease for additional 48,000 square feet to expand its facility

The International Multiple Sclerosis Management Practice (IMSMP), a 34,000 square foot research and treatment center dedicated to MS, today announced that it has signed a lease for an additional 48,000 square feet. This makes it the largest establishment in the world committed to discovering the cause and cure for MS.

20 Jan 2010

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA -- a leading company in conducting early-stage discovery research programs for the life science industry -- to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).

20 Jan 2010

Neurosurgical journals influence neurosurgeons and their patients

A compendium of articles in the Journal of Neurosurgery (JNS) provides evidence that specialty medical journals are not only an invaluable resource to physicians and researchers, but to the media and public. Clinical and basic science papers do not have to be published in large, high-impact publications to garner attention, and in fact when it comes to specialized areas of medicine such as neurosurgery, publications devoted to the subspecialty produce many citation classics. "Citation classic" is a term given to articles that have been cited more than 400 times.

18 Jan 2010

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

People with Parkinson's Disease are more likely to display abnormal social behaviour and make poor decisions in ambiguous circumstances if they are pathological gamblers, according to research in the January issue of the European Journal of Neurology.

18 Jan 2010

New research shows migraine and depression may share common genetic pathways

New research shows that migraine and depression may share a strong genetic component. The research is published in the January 13, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

18 Jan 2010

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

A breakthrough discovery by scientists at the University of Kentucky could someday lead to new treatments for a variety of diseases of the brain, spinal cord and the eye.

18 Jan 2010

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

TCA Cellular Therapy, LLC (TCA-CT) announced today that the U.S. Food and Drug Administration (FDA) has approved its adult stem cell protocol to conduct Phase I clinical trials to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).

18 Jan 2010

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

Medical Marijuana Inc applauds the New Jersey State Assembly and Senate for having approved "The New Jersey Compassionate Use Medical Marijuana Act" on Monday, January 11, 2010. A804/S119 removes state-wide penalties for possession of up to two ounces of marijuana when a New Jersey licensed Physician recommends it for one of the qualified medical conditions including Aids, Cancer, Multiple Sclerosis and Crohn's disease among others.

13 Jan 2010

In-home virtual reality videogames improve hand function in teens with hemiplegic cerebral palsy

Remotely monitored in-home virtual reality videogames improved hand function and forearm bone health in teens with hemiplegic cerebral palsy, helping them perform activities of daily living such as eating, dressing, cooking, and other tasks for which two hands are needed.

13 Jan 2010

New Jersey to legalize medical marijuana

The New York Times: "The New Jersey Legislature approved a measure on Monday that would make the state the 14th in the nation, but one of the few on the East Coast, to legalize the use of marijuana to help patients with chronic illnesses.

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists Extavia (Interferon beta 1b).

12 Jan 2010

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Plexxikon Inc. announces that enrollment has been initiated and the first patient has been dosed in a pivotal Phase 3 trial of PLX4032 (RG7204) in patients with metastatic melanoma. PLX4032 is a novel, oral and highly targeted drug that is designed to inhibit the BRAF cancer-causing mutation that occurs in about 50 percent of melanomas and about eight percent of all solid tumors. The randomized, controlled, Phase 3 “BRAF Inhibitor in Melanoma” (BRIM3) trial in previously untreated patients is part of the planned registration program for PLX4032.

9 Jan 2010

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Vitamin D insufficiency associated with higher risk of relapse attacks in patients with MS

CMO to manufacture Gaia BioPharma's GAI-122 Mitochondria-targeted neuroprotective agent

Results of two pivotal Phase III clinical trials with oral FTY720 published

COTI's novel small molecule effective against pancreatic cancer in animal model

EMD Serono announces results from CLARITY Phase III trial in MS patients

New method for diagnosing post-traumatic stress disorder

IMSMP signs a lease for additional 48,000 square feet to expand its facility

Fast Forward, JDRF announce collaborative partnership with Axxam SpA

Neurosurgical journals influence neurosurgeons and their patients

Dopamine replacement therapy causes brain dysfunction in patients with Parkinson disease, study says

New research shows migraine and depression may share common genetic pathways

Breakthrough discovery could lead to new treatments for a variety of CNS disorders

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

Medical Marijuana praises New Jersey State Assembly for removing state-wide penalties on marijuana use

In-home virtual reality videogames improve hand function in teens with hemiplegic cerebral palsy

New Jersey to legalize medical marijuana

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

BioTrends Research Group releases Wave One LaunchTrends: EXTAVIA report

Plexxikon commences dosing in PLX4032 Phase 3 trial for metastatic melanoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Sclerosis News and Research

Latest Multiple Sclerosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in